14 July 2022

Nintedanib for treating interstitial lung disease in children aged 6 to 17 years old

Nintedanib is a drug that is being investigated for use in patients aged 6 to 17 years old. Childhood ILD (chILD) is a group of over 200 rare lung conditions that are grouped together as they all share features such as inflammation that causes scaring in the lungs, resulting in irreversible breathing problems. Currently there are no licensed treatments for fibrosing ILD for children and adolescents.